Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Jun
13
Today In Oncology
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
Long-Term Outcomes of Adjuvant Hypofractionated Radiotherapy for Breast Cancer
Machine Learning Model May Improve Accuracy of Liquid Biopsy Results
FDA Approval in Renal Cell Carcinoma Adjuvant Belzutifan With Pembrolizumab
FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo